UK HealthCare logo

Practice areas

  • Carcinoid and Neuroendocrine Cancer Team
  • Gastrointestinal and Colorectal Cancer Team
  • Liver Cancer Team
  • Pancreas Cancer Team
  • Surgical Oncology

Faculty rank

Assistant Professor of Surgery

Clinic information

Clinical interests

  • Biliary Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Liver Cancer
  • Neuroendocrine Cancer
  • Pancreatic Cancer
  • Sarcoma
  • Surgical Oncology

Education

Degree

University of Alabama, School of Medicine, Birmingham

Residency

University of Alabama, School of Medicine, Birmingham

Fellowship

Hepato-Pancreato-Biliary (HPB) Surgery, University of Texas MD Anderson Cancer Center, Houston
Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston
Surgical Oncology Research, University of Alabama at Birmingham, Birmingham

Certifications or Special training

American Board of Surgery (ABS)
Society of Surgical Oncology (SSO)
Americas Hepato-Pancreato-Biliary Association (AHPBA)

Additional information

Profile

National Clinical Research Awards

SSO Essay Award for Best Clinical Research Paper (2013)
Pancreas Club PANCAN Oral Presentation Award (2013)
SSAT Presidential Plenary/Oral Presentation Award (2013)
AHPBA Presidential Plenary/Young Investigator Award (2012)
SSO Essay Award for Best Basic Science Research Paper (2007)

My name is Ching-Wei D. Tzeng; I specialize in the modern surgical treatment of tumors of the liver, pancreas, bile duct, stomach and upper gastrointestinal tract. I also see patients with colorectal, neuroendocrine and other abdominal cancers with liver metastases. I am a part of a team at UK Markey Cancer Center dedicated to the multidisciplinary evaluation and treatment of gastrointestinal cancers.

Research/Publications

Le AT, Tzeng CD. Does finding early recurrence improve outcomes, and at what cost? J Surg Oncol. 2016 Jul 8.

Saeed H, Hnoosh D, Huang B, Durbin EB, McGrath PC, Desimone P, Maynard E, Anthony LB, Dineen SP, Hosein PJ, Tzeng CD. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. J Surg Oncol. 2016 May 30.

Vilchez V, Turcios L, Zaytseva Y, Stewart R, Lee EY, Maynard E, Shah MB, Daily MF, Tzeng CD, Davenport D, Castellanos AL, Krohmer S, Hosein PJ, Evers BM, Gedaly R. Cancer stem cell marker expression alone and in combination with microvascular invasion predicts poor prognosis in patients undergoing transplantation for hepatocellular carcinoma. Am J Surg. 2016 Feb 27.